BAP1 gene cancer-risk study and family cancer patterns
Part of Cancer, Digestive system, Eyes & vision, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This study looks at how the BAP1 gene affects cancer risk and what cancers people develop, including within families. You may be able to join if you have a known BAP1-related mutation, a strong family cancer history, or a concerning cancer pattern linked to BAP1.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a known BAP1 pathogenic (harmful) or likely harmful gene variant, or a documented BAP1-related case in your family
- OR you have had at least one cancer that can occur with BAP1 and at least two close relatives with BAP1-related cancers
- OR you have had two or more BAP1-related cancers yourself
- OR you are a close relative of someone with a documented BAP1 mutation (even if you never had cancer)
- You can participate in an English consent process (the study materials are only available in English)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well advanced scans, liquid biopsy tests, and small follow-up procedures can find early mesothelioma in people with a high-risk BAP1 gene condition. It may help catch cancer earlier when treatment could work better.
This study follows people with a harmful (deleterious) BAP1 gene change to learn how it affects health over time. It may help researchers better understand mesothelioma risk and the long-term outcomes for families with this genetic mutation.
This study looks for new inherited genes linked to uveal melanoma (an eye cancer). If you have this cancer and don't already have a known genetic cause, you may be able to help find new genes that affect cancer risk.
This study tests a chemotherapy drug called temozolomide for people with advanced melanoma (skin cancer) that has a specific genetic change called BAP1. The drug may help shrink tumors or slow the cancer's growth, especially for people who have already tried other treatments.
This study tests an oral medication called decitabine/cedazuridine (INQOVI) that may help delay or prevent progression in people with early-stage mesothelioma who carry a BAP1 mutation. The treatment is given as a pill and aims to reactivate genes that may help control cancer growth.
This study looks at inherited (family) risk for childhood cancers, including families with early cancers or known cancer risk conditions. It may help researchers understand why some children get cancer and improve future risk detection and care.
Hear when a new Uveal Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.